Exploration of novel therapies for treatment of allergic diseases have highlighted measures which decrease IgE levels, and target Th2 cytokines (e.g. IL-4, IL-5, IL-31) thought to be implicated in control of those levels and other cell populations (eosinophils/basophils) implicated in allergic disease [29–33]. Here, IL4 is linked to allergic disease.